Colorectal cancer pharmacogenomics

Current Colorectal Cancer Reports

Volumn 2, Issue 4, 2006, Pages 217-224

  Marsh, Sharon ^a   Yu, Jinsheng ^a   Hoskins, Janelle M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 41549168878     PISSN: 15563790     EISSN: 15563804     Source Type: Journal    
DOI: 10.1007/s11888-006-0026-7     Document Type: Review

References (64)

1. Evans WE, Relling MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999, 286:487-491.
2. Sargent DJ, Niedzwiecki D, O'Connell MJ, Schilsky RL: Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 2001, 345:144-145.
3. Evans WE, McLeod HL: Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003, 348:538-549.
4. Watters JW, McLeod HL: Recent advances in the pharmacogenetics of cancer chemotherapy. Curr Opin Mol Ther 2002, 4:565-571.
5. Saltz LB, Cox JV, Blanke C, et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000, 343:905-914.
6. Goldberg RM, Sargent DJ, Morton RF, et al.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004, 22:23-30.
7. Hoff PM, Pazdur R: Progress in the development of novel treatments for colorectal cancer. Oncology 2004, 18:705-708.
8. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al.: Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005, 23:3502-3508.
9. Cunningham D, Humblet Y, Siena S, et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345.
10. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
11. Marsh S, Kwok P, McLeod HL: SNP databases and pharmacogenetics: great start, but a long way to go. Hum Mutat 2002, 20:174-179.
12. Wheeler DL, Barrett T, Benson DA, et al.: Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 2005, 33:D39-45.
13. Marsh S, McLeod HL: Pharmacogenomics: from bedside to clinical practice. Hum Mol Genet 2006, 15(Suppl 1):R89-93.
14. Beutler E, Gelbart T, Demina A: Racial variability in the UDPglucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A 1998, 95:8170-8174.
15. Iyer L, Hall D, Das S, et al.: Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 1999, 65:576-582.
16. Iyer L, Das S, Janisch L, et al.: UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002, 2:43-47.
17. Innocenti F, Undevia SD, Iyer L, et al.: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004, 22:1382-1388.
18. Paoluzzi L, Singh AS, Price DK, et al.: Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J Clin Pharmacol 2004, 44:854-860.
19. Ando Y, Saka H, Ando M, et al.: Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000, 60:6921-6926.
20. Marcuello E, Altes A, Menoyo A, et al.: UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 2004, 91:678-682.
21. FDA clears Third Wave pharmacogenetic test. Pharmacogenomics 2005, 6:671-672.
22. Han JY, Lim HS, Shin ES, et al.: Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 2006, 24:2237-2244.
23. Carlini LE, Meropol NJ, Bever J, et al.: UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/ irinotecan. Clin Cancer Res 2005, 11:1226-1236.
24. Colhoun HM, McKeigue PM, Davey Smith G: Problems of reporting genetic associations with complex outcomes. Lancet 2003, 361:865-872.
25. Heggie GD, Sommadossi JP, Cross DS, et al.: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987, 47:2203-2206.
26. Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH: High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 2002, 12:555-558.
27. Wei X, Elizondo G, Sapone A, et al.: Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics 1998, 51:391-400.
28. van Kuilenburg AB: Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004, 40:939-950.
29. Collie-Duguid ES, Etienne MC, Milano G, McLeod HL: Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 2000, 10:217-223.
30. Glasgow SC, Yu J, Carvalho LP, et al.: Unfavourable expression of pharmacologic markers in mucinous colorectal cancer. Br J Cancer 2005, 92:259-264.
31. Watson MA, Stewart RK, Smith GB, et al.: Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 1998, 19:275-280.
32. Ishimoto TM, Ali-Osman F: Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli. Pharmacogenetics 2002, 12:543-553.
33. Stoehlmacher J, Park DJ, Zhang W, et al.: Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 2002, 94:936-942.
34. Stoehlmacher J, Park DJ, Zhang W, et al.: A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004, 91:344-354.
35. Lecomte T, Landi B, Beaune P, et al.: Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 2006, 12:3050-3056.
36. Watters JW, McLeod HL: Cancer pharmacogenomics: current and future applications. Biochim Biophys Acta 2003, 1603:99-111.
37. Lenz HJ: The use and development of germline polymorphisms in clinical oncology. J Clin Oncol 2004, 22:2519-2521.
38. Cheng Q, Yang W, Raimondi SC, et al.: Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes. Nat Genet 2005, 37:878-882.
39. McLeod HL, Marsh S: Pharmacogenetics goes 3D. Nat Genet 2005, 37:794-795.
40. Rooney PH, Murray GI, Stevenson DA, et al.: Comparative genomic hybridization and chromosomal instability in solid tumours. Br J Cancer 1999, 80:862-873.
41. Marsh S, Mallon MA, Goodfellow P, McLeod HL: Concordance of pharmacogenetic markers in germ-line and colorectal tumor DNA. Pharmacogenomics 2005, 6:873-877.
42. Sinicrope FA, Rego RL, Halling KC, et al.: Thymidylate synthase expression in colon carcinomas with microsatellite instability. Clin Cancer Res 2006, 12:2738-2744.
43. Lamberti C, Lundin S, Bogdanow M, et al.: Microsatellite instability did not predict individual survival of unselected patients with colorectal cancer. Int J Colorectal Dis 2006, [Epub ahead of print].
44. Johnston PG, Fisher ER, Rockette HE, et al.: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994, 12:2640-2647.
45. Allegra C: Thymidylate synthase levels: prognostic, predictive, or both? J Clin Oncol 2002, 20:1711-1713.
46. Popat S, Matakidou A, Houlston RS: Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2004, 22:529-536.
47. Bendardaf R, Lamlum H, Elzagheid A, et al.: Thymidylate synthase expression levels: a prognostic and predictive role in advanced colorectal cancer. Oncol Rep 2005, 14:657-662.
48. Edler D, Glimelius B, Hallstrom M, et al.: Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 2002, 20:1721-1728.
49. Marsh S: Thymidylate synthase pharmacogenetics. Invest New Drugs 2005, 23:533-537.
50. McLeod HL, Tan B, Malyapa R, et al.: Genotype-guided neoadjuvant therapy for rectal cancer. Proc Am Soc Clin Oncol 2005, 23:197.
51. Boyer J, Allen WL, McLean EG, et al.: Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res 2006, 66:2765-2777.
52. Maxwell PJ, Longley DB, Latif T, et al.: Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling. Cancer Res 2003, 63:4602-4606.
53. Wang Y, Jatkoe T, Zhang Y, et al.: Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 2004, 22:1564-1571.
54. Garrity MM, Burgart LJ, Mahoney MR, et al.: Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study. J Clin Oncol 2004, 22:1572-1582.
55. Allegra CJ, Paik S, Colangelo LH, et al.: Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 2003, 21:241-250.
56. Yu J, Shannon WD, Watson MA, McLeod HL: Gene expression profiling of the irinotecan pathway in colorectal cancer. Clin Cancer Res 2005, 11:2053-2062.
57. Kidd EA, Yu J, Li X, et al.: Variance in the expression of 5-fluorouracil pathway genes in colorectal cancer. Clin Cancer Res 2005, 11:2612-2619.
58. Wang TL, Diaz LA Jr, Romans K, et al.: Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci U S A 2004, 101:3089-3094.
59. Yu J, Zhang W, McLeod HL: Pharmacogenomic assessment on topoisomerase 1 and thymidylate synthase gene copy number in colorectal cancer [abstract]. Presented at the annual meeting of the American Association for Cancer Research. Washington, DC; April 1-5, 2006.
60. Moroni M, Veronese S, Benvenuti S et al.: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005, 6:279-286.
61. Gagnon JF, Bernard O, Villeneuve L, et al.: Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer. Clin Cancer Res 2006, 12:1850-1858.
62. Ezzeldin HH, Lee AM, Mattison LK, Diasio RB: Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin Cancer Res 2005, 11:8699-8705.
63. Noguchi T, Tanimoto K, Shimokuni T, et al.: Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells. Clin Cancer Res 2004, 10:7100-7107.
64. Yu J, McLeod HL, Ezzeldin HH, Diasio RB: Methylation of the DPYD promoter and dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 2006, 12:3864.